Generic growth
HOME > PAST ISSUE > COVER STORY [Premium content]September 2007
China is coming from behind and challenging India in an industry it has traditionally dominated
During the first week of August, drug multinational (MNC) Novartis suffered a setback in India when it lost a legal challenge to the country’s patent law.
After being refused a patent for Glivec, a leukemia drug, the company moved to challenge the validity of India’s patent law, which does not protect incremental innovations. The company launched several lawsuits, including one that said the law went against WTO rules.
On August 7, a court in the southern ...
After being refused a patent for Glivec, a leukemia drug, the company moved to challenge the validity of India’s patent law, which does not protect incremental innovations. The company launched several lawsuits, including one that said the law went against WTO rules.
On August 7, a court in the southern ...
log in to continue reading...
 |
To receive the best China business news that the market has to offer,
subscribe to the China Economic Review.
subscribe to the China Economic Review.